In this article, we will discuss Ponatinib (Dosage Overview). So, let’s get started.
Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase
chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Ponatinib.
The recommended dose and schedule for Ponatinib is 45 mg administered orally once daily. Continue treatment as long as the patient does not show evidence of disease progression or unacceptable toxicity. Ponatinib may be taken with or without food. Tablets should be swallowed whole.